Myasthenia GravisMyaRESPNCT06866652
Evaluating Dyspnea in Autoimmune Myasthenia Gravis "Why am I Short of Breath?"
An observational study of Myasthenia Gravis and Dyspnea, run by Institut de Myologie, France at 1 site in France.
Trial summary
Individuals with MG (IwMG) experience shortness of breath that may be activity-related, occur at rest and even happen during sleep. Dyspnea is a complex, multidimensional and multifactorial symptom involving sensory perception, cognition and emotion. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Myasthenia Gravis, Dyspnea
- How many people
- 50 participants
- Where
- 1 siteFrance
- Study dates
- 8 Apr 2026to Jun 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Age ≥18 Confirmed diagnosis of autoimmune MG Shortness of breath in daily life: score 1 or 2 on the respiration item on the MG- activities of daily living score
Who may be able to join
- Age ≥18
- Confirmed diagnosis of autoimmune MG
- Shortness of breath in daily life: score 1 or 2 on the respiration item on the MG- activities of daily living score
- Signed consent form
- Affiliated to or beneficiary of a social security scheme
Who cannot join
- Known Pregnancy
- Known respiratory disorder (other than MG)
- Recent (within past 4 weeks) respiratory infection
- Current MG crisis or exacerbation (necessitating increase in MG medication \&/or hospital admission)
- No dyspnea - score 0 or 3 on the respiration item on the MG- activities of daily living score
- Severe cognitive impairment/guardianship
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Institute of Myology
Paris
Simone Birnbaum, +33 1 42 16 58 79, s.birnbaum@institut-myologie.org
About this study
Individuals with MG (IwMG) experience shortness of breath that may be activity-related, occur at rest and even happen during sleep. Dyspnea is a complex, multidimensional and multifactorial symptom involving sensory perception, cognition and emotion. Identifying the cause(s) of dyspnea in MG may assist in finding therapeutic strategies, reducing discomfort, improving QoL and potentially limiting respiratory deterioration and incidence of MG crisis.
Read the detailed description
MYaResp is a prospective observational, cross-sectional study to evaluate dyspnea in adults with autoimmune myasthenia gravis.
Study aims include to:
- Describe the characteristics of dyspnea in IwMG
- Understand contributing factors and factors associated with dyspnea in IwMG including the relationship between patient-reported dyspnea, disease severity and functional limitations.
- Determine the most effective tests to identify the causes and contributing factors of dyspnea
- Conditions
- Myasthenia Gravis, Dyspnea
- Keywords
- dyspnea, breathlessness, respiratory
- Medical subject headings
- Myasthenia Gravis, Dyspnea
What is being measured
The primary outcome is the main question the study is designed to answer.
Dyspnea questionnaires
Dyspnea-12
Measured: baseline
Secondary outcomes (5)
cardiopulmonary exercise test
cycle ergometer
Measured: baseline
Polysomnography
evaluation of sleep disordered breathing
Measured: baseline
Functional measures
6 minute walk test
Measured: baseline
Quality of life questionnaires
Revised version of the myasthenia gravis quality of life questionnaire (Burns, French validation Birnbaum)
Measured: baseline
Anxiety and depression
Hospital Anxiety and Depression Scale
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Mar 2025
- Study start8 Apr 2026
- Primary completionJun 2028 (estimated)
- Study completionJun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myasthenia GravisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Institut de Myologie, France
- Sponsor type
- University, hospital or other
- Collaborators
- APHP
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06866652
- Sponsor's protocol ID
- MyaRESP
- Acronym
- MyaRESP
- Status last verified
- May 2026
- First submitted
- 20 Feb 2025
- Last updated
- 8 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluating Dyspnea in Autoimmune Myasthenia Gravis "Why am I Short of Breath?"
- ClinicalTrials.gov ID
- NCT06866652
- Acronym / sponsor ID
- MyaRESP / MyaRESP
- Conditions
- Myasthenia Gravis, Dyspnea
- Keywords
- dyspnea, breathlessness, respiratory
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Institut de Myologie, FranceUniversity, hospital or other
- Collaborators
- APHP
- Study start
- 8 Apr 2026 (actual)
- Primary completion
- Jun 2028 (estimated)
- Study completion
- Jun 2028 (estimated)
- First posted
- 10 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Individuals with MG (IwMG) experience shortness of breath that may be activity-related, occur at rest and even happen during sleep. Dyspnea is a complex, multidimensional and multifactorial symptom involving sensory perception, cognition and emotion. Identifying the cause(s) of dyspnea in MG may assist in finding therapeutic strategies, reducing discomfort, improving QoL and potentially limiting respiratory deterioration and incidence of MG crisis.
Detailed description
MYaResp is a prospective observational, cross-sectional study to evaluate dyspnea in adults with autoimmune myasthenia gravis.
Study aims include to:
- Describe the characteristics of dyspnea in IwMG
- Understand contributing factors and factors associated with dyspnea in IwMG including the relationship between patient-reported dyspnea, disease severity and functional limitations.
- Determine the most effective tests to identify the causes and contributing factors of dyspnea
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Age ≥18 Confirmed diagnosis of autoimmune MG Shortness of breath in daily life: score 1 or 2 on the respiration item on the MG- activities of daily living score
Key inclusion criteria (5 listed)
- Age ≥18
- Confirmed diagnosis of autoimmune MG
- Shortness of breath in daily life: score 1 or 2 on the respiration item on the MG- activities of daily living score
- Signed consent form
- Affiliated to or beneficiary of a social security scheme
Key exclusion criteria (6 listed)
- Known Pregnancy
- Known respiratory disorder (other than MG)
- Recent (within past 4 weeks) respiratory infection
- Current MG crisis or exacerbation (necessitating increase in MG medication \&/or hospital admission)
- No dyspnea - score 0 or 3 on the respiration item on the MG- activities of daily living score
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Dyspnea questionnaires
Time frame: baseline
Dyspnea-12
5 secondary outcomes
cardiopulmonary exercise test
Time frame: baseline
Polysomnography
Time frame: baseline
Functional measures
Time frame: baseline
Quality of life questionnaires
Time frame: baseline
Anxiety and depression
Time frame: baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 May 2026.
- Individual participant dataSharing planned: No
Related trials for Myasthenia Gravis
Active, not recruitingPhase 3
An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Ocular Myasthenia Gravis
Active, not recruiting
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis
RecruitingPhase 3
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Ocular Myasthenia Gravis
Recruiting
Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360
Myasthenia Gravis, Generalized
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Myasthenia Gravis and Dyspnea, run by Institut de Myologie, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Dyspnea questionnaires (time frame: baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2026.